IPCA Laboratories is acquiring 33.38% from the promoters of Unichem Laboratories (UL). Promoters before this transaction owned 50.94% of UL. Out of the balance, 9.85% was held by the institutions and 39.21% by the retail investors. Â Transaction is announced @ Rs 440/ share aggregating to Rs 1,034.06 cr. This implies a premium of about 17% … Read more
As per newspaper reports, Sanofi India is working on spinning off it’s consumer healthcare business in India in a separate listed entity. The subject unit’s products include leading anti-allergy brands such as Allegra and Avil, pain management drug Combiflam and Vitamin D brand Depura. The business posted revenue of Rs 1,000-1,250 crore in CY22 (against … Read more
The government on Tuesday cancelled the licences of 18 pharmaceutical companies for manufacturing of spurious medicines following an inspection by the Drugs Controller General of India (DCGI) on 76 companies across 20 states. “Huge crackdown under way on pharma companies across the country related to manufacturing of spurious medicines,” news agency ANI reported quoting sources. … Read more
Sanofi’s asthma drug Dupixent met all targets in a trial to treat “smoker’s lung”, potentially adding billions to the French drugmaker’s growth prospects, but also underscoring a heavy reliance on its bestseller. In a late stage trial Dupixent, jointly developed with Regeneron, led to a 30% reduction in moderate or severe acute exacerbations of chronic … Read more
Eris Lifesciences is acquiring 9 dermatology brands from Glenmark Pharma. The brands are – Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands. The acquisition is for the India and Nepal Territories Consideration for the transaction is Rs 340 crore payable in cash. Turnover of the acquired brands: FY 20 – … Read more